Thailand vs Uganda: Average cost of drugs for extensively drug-resistant tuberculosis
Thailand
1,561 constant 2022 US$
in 2024
Uganda
1,709 constant 2022 US$
in 2024
Thailand rank
32nd
Uganda rank
30th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Thailand
- Uganda
How they compare
Uganda currently reports 1,709 constant 2022 US$ against 1,561 constant 2022 US$ in Thailand, a difference of 148 constant 2022 US$.
That makes Uganda's figure about 1.1 times Thailand's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Thailand ahead.
Thailand ranks 32nd and Uganda ranks 30th of 56 countries.
Across the 2 decades both report, Thailand averaged higher in 1 and Uganda in 1.
Head to head by decade
| Decade | Thailand | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,958 constant 2022 US$ | 3,356 constant 2022 US$ | 602.67 constant 2022 US$ | Thailand |
| 2020s | 2,431 constant 2022 US$ | 3,247 constant 2022 US$ | 816.2 constant 2022 US$ | Uganda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Thailand or Uganda?
- Uganda, at 1,709 constant 2022 US$ against 1,561 constant 2022 US$ in Thailand as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Thailand and Uganda?
- 148 constant 2022 US$, with Uganda ahead.
- How many years of comparable data are there for Thailand and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Thailand and Uganda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Thailand ranks 32nd and Uganda ranks 30th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.